Potassium voltage-gated channel subfamily G member 3 (KCNG3)
Target
KCNG3
Molecular classification
Ion channel subunit (regulatory/modulatory subunit), Voltage-gated potassium channel family, subfamily G (gamma subunit), Other: “Electrically silent” K v channel subunit (does not form functional homotetramers)
01
Overview
Potassium voltage-gated channel subfamily G member 3 (KCNG3, Kv6.3) is a regulatory “electrically silent” subunit of the voltage-gated potassium channel family. It does not form functional channels on its own but coassembles with functional pore-forming subunits (such as KCNB1/Kv2.1) to modulate the kinetics of potassium currents in excitable cells. KCNG3 is expressed in both neuronal and non-neuronal tissues and contributes to the fine-tuning of excitability, action potential repolarization, and related physiological functions. Altered expression of KCNG3 has been implicated in several disease contexts, including neuropsychiatric disorders, cardiovascular pathologies, and certain cancers. There are currently no drugs or approved selective modulators targeting KCNG3 directly, but its regulatory effects on channel function underline its relevance as a molecular target in pathophysiological processes.
Other names
KCNG3Kv6.3Potassium channel, voltage-gated, modifier subfamily G, member 3
02
Mechanism of action
KCNG3 acts as a regulatory (gamma) subunit and modifies the gating, inactivation, and deactivation kinetics of heterotetrameric Kv channels containing functional alpha subunits (such as Kv2.1).
It does not form functional channels alone, but in combination with other Kv subunits, alters ion flux and cell excitability.
03
Biological functions
Modulation of voltage-gated potassium channel current propertiesRegulation of neuronal excitabilityControl of action potential kinetics/repolarizationFine-tuning of excitable cell electrophysiology (e.g., neurons, smooth muscle cells)Involvement in regulation of apoptosis, proliferation, and vascular tone by influencing partner Kv channels in some non-neuronal tissues
04
Disease associations
Neurodegenerative disease (via neuronal excitability modulation; associated with neurological disorders, though direct causal links are not fully established)Cardiovascular disease (alteration in smooth muscle electrophysiology and hypertension links in animal models)Cancer (high expression in some cancers, e.g., gastric cancer, associated with poor prognosis)Gastrointestinal motility disorders (decreased expression in Hirschsprung disease colonic segments)Cardiomyopathy (associated: arrhythmogenic right ventricular cardiomyopathy)Retinal disease (associated: retinal cone dystrophy 3B)
05
Safety considerations
Since KCNG3 modulates channel kinetics rather than being a pore-forming channel itself, direct blockade or activation could have off-target effects by broadly altering excitability of excitable tissues (potential pro-arrhythmic, pro-convulsive, or neuropsychiatric effects).No direct therapeutic agents or adverse safety findings specific to KCNG3 modulation are reported.Theoretical safety concerns relate to unintended systemic alterations in tissues where KCNG3 coassembles with other Kv channels (neurons, heart, smooth muscle, etc.)
06
Biomarkers
Expression level of KCNG3 may serve as a biomarker in some cancers (e.g., gastric cancer, where high KCNG3 correlates with poor prognosis).Downregulation may be a biomarker for Hirschsprung disease in colonic tissue.No established clinical biomarkers for drug response or patient selection are available.
Beyond the preview
Go deeper on Potassium voltage-gated channel subfamily G member 3 (KCNG3).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Drug pipeline
Full profile access
Explore the programs pursuing this target and their development progress.
Drug candidates
Developers
Development stage
Clinical trials
Full profile access
Follow the clinical studies evaluating therapies directed at this target.
Trial design
Status
Readouts
Competitive landscape
Full profile access
Compare approaches across drug candidates, modalities, and indications.
Programs
Modalities
Indications
Literature & evidence
Full profile access
Investigate the research and source evidence behind target biology and development.
Publications
Sources
Analysis
Patents
Full profile access
Explore patent activity around therapies and technologies addressing this target.
Patents
Assignees
Technologies
Research & analysis
Full profile access
Connect target biology, drug development, and emerging evidence in your research.
Biology
Development news
Analysis
Bring the full picture into focus.
See how Gosset can support your research on Potassium voltage-gated channel subfamily G member 3 (KCNG3).